NH130 is a highly selective serotonin 5-HT2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis.[3][1][4][2] It is taken orally.[1][2] The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours.[2] NH130 is under development by Jiangsu Nhwa Pharmaceutical in China.[3][1][2] As of November 2025, it is in phase 2 clinical trials.[3]
| Clinical data | |
|---|---|
| Other names | NH-130 |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin 5-HT2A receptor antagonist; Antipsychotic |
| Pharmacokinetic data | |
| Onset of action | 3.0–4.5 hours (Tmax |
| Elimination half-life | 13.7–18.2 hours[2] |
See also
editReferences
edit- 1 2 3 4 "NH-130 Drug Profile". Ozmosi. Retrieved 18 January 2026.
- 1 2 3 4 5 6 Zhang K, Zhao S, Du J, Zhang L (2024). "Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling". Frontiers in Pharmacology. 15 1474868. doi:10.3389/fphar.2024.1474868. PMC 11424876. PMID 39329116.
Following the success of pimavanserin, the search for new molecules with enhanced efficacy and an improved safety profile for treating PDP began. In Phase 1 clinical trial (CTR20230409), healthy volunteers received the compound NH130, a highly selective inverse agonist of the 5-HT2AR designed to mimic pimavanserin. The results confirmed NH130's favourable safety and tolerability. Based on these findings, further optimization of the compound and Phase 2 studies in patients with PDP are planned (K. Zhang et al., 2024).
- 1 2 3 "Delving into the Latest Updates on NH-130 with Synapse". Synapse. 21 November 2025. Retrieved 18 January 2026.
- ↑ Fryc M, Kluzik D, Czopek A, Jończyk J, Zagórska A (November 2025). "Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases". Neuropharmacology. 279 110622. doi:10.1016/j.neuropharm.2025.110622. PMID 40752586.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |